IP Library Granted Patent US 10,203,327
Granted Patent B2
US 10,203,327 · App. 15/034,721 · Granted Feb 12, 2019

Organic compounds

Inventors: Frederic Bassilana (Basel, CH); Birgit Uta Baumgarten (Riehen, CH); Nathalie Marie-Therese Carte (Huningue, FR); Michel Detheux (Mignault, BE); Rocco Falchetto (Basel, CH); Sebastien Hannedouche (Temploux, BE); Vincent Lannoy (Liernu, BE); Keith Mansfield (Shrewsbury, MA); Klaus Peter Seuwen (Michelbach le Bas, FR); Thomas Laurent Henri Suply (Zimmersheim, FR)
Assignees: Novartis AG; Odega S.A.
G01N33/566C07K16/28G01N2333/4719
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,203,327
App. No.
15/034,721
Granted
Feb 12, 2019
Kind
B2
Abstract

The present invention relates to modulators of the interaction between G-protein coupled receptor 15(GPR15) and c10orf99. The modulator may be a small chemical molecule, antibody or other therapeutic protein. Methods of medical treatment and methods of identifying modulators are also described.

Claims (15)

1. A method of identifying a modulator of the binding between C10orf99 and GPR15 which method comprises;

(a) providing a candidate modulator;

(b) incubating the modulator of step (a) with C10orf99 having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6 and GPR15 having the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11;

(c) determining whether the binding between C10orf99 with GPR15 is modulated in the presence of said candidate modulator compared to the binding between C10orf99 with GPR15 in the absence of said candidate modulator.

2. A method of identifying an agent that modulates the binding between c10orf99 and GPR15, said method comprising:

(a) contacting GPR15 having the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11 with c10orf99 having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6 in the presence and absence of a candidate modulator under conditions permitting the binding of said c10orf99 to said GPR15; and

(b) measuring the binding of said GPR15 to said c10orf99, wherein a decrease in binding in the presence of said candidate modulator, relative to the binding in the absence of said candidate modulator, identifies said candidate modulator as an agent that modulates the function of binding between c10orf99 and GPR15.

3. A method of identifying an agent that modulates the signaling activity of GPR15, said method comprising:

(a) contacting GPR15 having the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11 with c10orf99 having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6 in the presence and absence of a candidate modulator; and

(b) measuring a signaling activity of said GPR15, wherein a change in the signaling activity in the presence of said candidate modulator relative to the signaling activity in the absence of said candidate modulator identifies said candidate modulator as an agent that modulates the signaling activity of GPR15.

4. A method of identifying an agent that increases the signaling activity of GPR15, said method comprising:

(a) contacting GPR15 having the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11 with a candidate modulator;

(b) measuring a signaling activity of said GPR15 in the presence of said candidate modulator; and

(c) comparing said signaling activity measured in the presence of said candidate modulator to said signaling activity measured in a sample in which said GPR15 is contacted with c10orf99 having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6 at its EC 50 , wherein said candidate modulator is identified as an agent that increases the signaling activity of GPR15 when the amount of said signaling activity measured in the presence of said candidate modulator is at least 50% of the amount induced by said c10orf99 present at its EC 50 .

5. The method of claim 3 or 4 , wherein the step of measuring a signaling activity comprises (i) detecting a change in the level of a second messenger, said second messenger being cAMP or intracellular calcium, or (ii) measuring guanine nucleotide binding or exchange, adenylatecyclase activity, Protein Kinase C activity, phosphatidylinositol breakdown, diacylglycerol, inositol triphosphate, arachinoid acid, MAP kinase activity, tyrosine kinase activity, or reporter gene expression.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2019
From: OGEDA SA
To: EPICS THERAPEUTICS
Reel/Frame 049433/0900 →
CHANGE OF NAME Recorded Sep 28, 2017
From: EUROSCREEN S.A.
To: ODEGA S.A.
Reel/Frame 044040/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2016
From: BASSILANA, FREDERIC; SEUWEN, KLAUS PETER; SUPLY, THOMAS LAURENT HENRI; CARTE, NATHALIE MARIE-THERESE; BAUMGARTEN, BIRGIT UTA
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
Reel/Frame 038656/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2016
From: MANSFIELD, KEITH
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
Reel/Frame 038656/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2016
From: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
To: NOVARTIS AG
Reel/Frame 038656/0174 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2016
From: FALCHETTO, ROCCO
To: NOVARTIS PHARMA AG
Reel/Frame 038656/0205 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2016
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 038656/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2016
From: HANNEDOUCHE, SEBASTIEN; DETHEUX, MICHEL; LANNOY, VINCENT
To: EUROSCREEN S.A.
Reel/Frame 038656/0285 →
Continuity (2)
Provisional Application 61899978 · Nov 5, 2013
Related Publication 20160274110A1 · Sep 22, 2016